Le Lézard
Classified in: Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Advisory

Axonics® Reports Preliminary Second Quarter 2020 Revenue

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited second quarter 2020 revenue and provided an operational update.

Recent Business and Financial Highlights

Raymond W. Cohen, CEO of Axonics, commented, "Axonics has stayed focused on supporting physicians and their patients during the COVID-19 pandemic, along with building finished goods inventory, signing agreements with national, regional and local hospital systems, and advancing regulatory filings with the FDA. In the second quarter, we continued to make meaningful progress on new customer acquisition, with over 45% of the top 1,000 centers in the United States now having implanted patients with the Axonics r-SNM System. While gross margins will be impacted by lower overhead absorption and other related factors, we are highly encouraged by the trajectory of new order flow in June. Given these factors, we are confident that Axonics is well positioned for growth in the second half of 2020, while recognizing that a sustained recovery in elective procedures is contingent on factors that are outside of our control."

Mr. Cohen continued, "We continue to invest in innovation and enhancing the patient experience, having announced several recent FDA approvals that will accrue to SNM becoming the preferred therapy for overactive bladder and bowel dysfunction. The overwhelmingly positive feedback from clinicians and patients on their experience with our product in tandem with our commitment to increase patient awareness supports our conviction that the SNM market is poised for significant expansion in the years ahead."

Axonics will report complete second quarter 2020 financial results and provide a further operational update after the market closes on August 6, 2020. The preliminary results set forth above are unaudited and remain subject to ongoing review and adjustment.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. The Axonics SNM therapy, which has been clinically proven to reduce symptoms and restore pelvic floor function, is now being offered at hundreds of medical centers across the U.S. and in dozens of select hospitals in Western Europe. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. The Axonics System is the first long-lived rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit the Company's website at www.axonics.com.

Forward-Looking Statements

Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as "planned," "expects," "believes," "anticipates," "designed," and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

These press releases may also interest you

at 16:05
PS Business Parks, Inc. today announced that Maria R. Hawthorne will retire as President and Chief Executive Officer of the Company, effective September 1, 2020. Ms. Hawthorne has been on medical leave of absence due to health issues unrelated to...

at 16:00
As parents continue to navigate everyday life through these challenging times, BooginHead, the beloved brand of baby and toddler essentials, extends their line to include new adjustable social distancing face masks just in time for back to school...

at 16:00
Gulf Coast Pharmaceuticals Plus (GCPP), a leading specialty pharmaceutical distributor based in Ocean Springs, Mississippi, recently donated hundreds of N95 respirator masks to fire departments across the United States. The donation comes as...

at 15:55
In a study published in Annals of Internal Medicine, Kaiser Permanente research shows that obesity was associated with a substantial increased risk of death from COVID-19. However, it also found that the risk of death from COVID-19 associated with...

at 15:50
The Ontario Council of Hospital Unions/CUPE (OCHU) and CUPE Ontario are hosting 22 rallies across the province outside PC MPP offices, asking that the government revoke the COVID-19 emergency orders that can indefinitely override front line workers'...

at 15:27
Cincinnati Financial Corporation announced that, at today's regular meeting, the board of directors declared a 60-cents-per-share regular quarterly cash dividend. The dividend is payable October 15, 2020, to shareholders of record as of September...

News published on 13 july 2020 at 06:05 and distributed by: